High frequency of activated NKp46⁺ natural killer cells in patients with new diagnosed of latent autoimmune diabetes in adults

References

• Brahmkshatriya, P. P., A. A. Mehta, B. D. Saboo, and R. K. Goyal. 2012. Characteristics and prevalence of latent autoimmune diabetes in adults (LADA). ISRN Pharmacol. 58: 202–210
   Google Scholar
• Szepietowska B., A. Głębocka, U. Puch, et al. 2012. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus. Arch. Med. Sci. 83: 491–495
   Google Scholar
• Guglielmi C., A. Palermo, and P. Pozzilli. 2012. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab. Res. Rev. 28: 40–46
   Web of Science ®Google Scholar
• Skorstad G., A. L. Hestvik, P. Torjesen, et al. 2008. GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence. Eur. J. Neurol. 15: 973–980
   PubMed Web of Science ®Google Scholar
• Ziegler, A. G., and E. Bonifacio. 2012. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55: 1937–1943
   Google Scholar
• Jayakrishnan, B., D. E. Hoke, C. G. Langendorf, et al. 2011. An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes. PLoS One 6: e18411
   Google Scholar
• Parikka, V., K. Näntö-Salonen, M. Saarinen, et al. 2012. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55: 1926–1936
   PubMedGoogle Scholar
• Ziegler, A. G., M. Pflueger, C. Winkler, et al. 2011. Accelerator progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J. Autoimmune. 37: 3–7
   Google Scholar
• Orban, T., J. M. Sosenko, D. Cuthbertson, et al; Diabetes Prevention Trial-Type 1 Study Group. 2009. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care 32: 2269–2274
   PubMed Web of Science ®Google Scholar
• Colucci, F., M. A. Caligiuri, and J. P. Di Santo. 2003. What does it take to make a natural killer? Nat. Rev. Immune. 3: 413–425
   PubMed Web of Science ®Google Scholar
• Baxter, A. G., and M. J. Smyth. 2002. The role of NK cells in autoimmune disease. Autoimmunity 35: 1–14
   PubMed Web of Science ®Google Scholar
• Johansson, S., L. Berg, H. Hall, and P. Hoglund. 2005. NK cells: elusive players in autoimmunity. Trends Immune. 26: 613–618
   PubMed Web of Science ®Google Scholar
• Boulet, S., M. Kleyman, J. Y. Kim, et al. 2008. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 22: 1487–1491
   PubMed Web of Science ®Google Scholar
• Parham, P. 2005. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immune. 5: 201–214
   PubMed Web of Science ®Google Scholar
• Rodacki, M., B. Svoren, V. Butty, et al. 2007. Alter natural killer cell in type 1 diabetic patients. Diabetes 56: 177–185
   PubMed Web of Science ®Google Scholar
• Qin, H., I. F. Lee, C. Panagiotopoulos, et al. 2011. Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling. Diabetes 60: 857–866
   Google Scholar
• Akesson, C., K. Uvebrant, C. Oderup, et al. 2010. Alter natural killer cell frequency and phenotype in latent autoimmune diabetes in adults prior to insulin deficiency. Clin. Exp. Immunol. 161: 48–56
   Google Scholar
• American Diabetes Association. 2011. Diagnosis and classification of diabetes mellitus. Diabetes Care 34: S62–S69
   PubMed Web of Science ®Google Scholar
• Fourlanos, S., F. Dotta, C. J. Greenbaum, et al. 2005. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48: 2206–2212
   PubMed Web of Science ®Google Scholar
• Baecher-Allan, C., J. A. Brown, G. J. Freeman, and D. A. Hafler. 2001. CD4+CD25 high regulatory cells in human peripheral blood. Immune 167: 1245–1253
   PubMed Web of Science ®Google Scholar
• Guo, H., B. Xu, L. Gao, et al. 2012. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. Exp. Biol. Med. (Maywood) 237: 556–562
   Web of Science ®Google Scholar
• Negishi, K., N. Waldeck, G. Chandy, et al. 1986. Natural killer cell and islet cell activities in type 1diabetes. Diabetologia 29: 352–357
   PubMed Web of Science ®Google Scholar
• Hussain, M. J., L. Alviggi, B. A. Millward, et al. 1987. Evidence that the reduced number of natural killer cells in type 1 (insulin-dependent) diabetes many be genetically determined. Diabetologia 30: 907–911
   Google Scholar
• Herold, K. C., A. Huen, L. Gould, et al. 1984. Alterations in lymphocyte subpopulations in type 1 diabetes melltius:exploration of possible mechanisms and relationshop to autoimmune phenomena. Diabetologia 27: 102–105
   PubMed Web of Science ®Google Scholar
• Nair, M. P., E. W. Lewis, and S. A. Schwartz. 1986. Immunoregulatory dysfuctions in type diabetes: natural and antibody-dependent cellular cytotoxic activities. J. Clin. Immunol. 6: 363–372
   Google Scholar
• Scheinin T., J. Maenpaa, and S. Kontiainen. 1990. Immune responses to Insulin and lymphocyte subclasses at diagnosis of insulin-dependent diabetes and one year later. Immunobiology 180: 431–440
   PubMedGoogle Scholar
• Zhou, Z., Y. Xiang, L. Ji, et al; LADA China Study Group. 2013. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62: 543–550
   PubMed Web of Science ®Google Scholar
• Palmer, J. P., G. A. Fleming, C. J. Greenbaum, et al. 2004. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve B-cell function report of an ADA workshop, 21–22 October 2001. Diabetes 53: 250–264
   PubMedGoogle Scholar
• Campbell, K. S., and J. Hasegawa. 2013. Natural killer cell biology: an update and future directions. J. Allergy Clin. Immunol 132: 536–544
   Google Scholar
• Choi, I. K., Y. Li, E. Oh, et al. 2013. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity. PLoS One 8: e67512
   PubMed Web of Science ®Google Scholar
• Mair, K. H., S. E. Essler, M. Patzl, et al. 2012. NKp46 expression discriminates porcine NK cells with different functional properties. Eur. J. Immunol. 42: 1261–1271
   PubMed Web of Science ®Google Scholar
• Pembroke, T. P. I., I. Rees, K. Gallagher, and P. Mizen. 2011. Reduced NK cell cytotoxicity in hepatitis C infection is associated with reduced levels of cytotoxicity markers NKP30 and NKP46. Gut 60: A243–A244
   Google Scholar